CN1535958A - α-取代的嘧啶-硫代烷基和烷基醚化合物 - Google Patents

α-取代的嘧啶-硫代烷基和烷基醚化合物 Download PDF

Info

Publication number
CN1535958A
CN1535958A CNA200410032589XA CN200410032589A CN1535958A CN 1535958 A CN1535958 A CN 1535958A CN A200410032589X A CNA200410032589X A CN A200410032589XA CN 200410032589 A CN200410032589 A CN 200410032589A CN 1535958 A CN1535958 A CN 1535958A
Authority
CN
China
Prior art keywords
dihydro
pyridyl
pyrimidine
chloro
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200410032589XA
Other languages
English (en)
Chinese (zh)
Inventor
R��A��ŵ�߿�
R·A·诺根特
Τʲ��
D·G·韦什卡
G·J·克里克
D·R·格拉伯
S·T·施拉克特
��Ī������
M·J·墨菲
J·默里斯
R·C·托马斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of CN1535958A publication Critical patent/CN1535958A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA200410032589XA 1995-05-08 1996-05-03 α-取代的嘧啶-硫代烷基和烷基醚化合物 Pending CN1535958A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43670895A 1995-05-08 1995-05-08
US08/436,708 1995-05-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB961937912A Division CN1152022C (zh) 1995-05-08 1996-05-03 α-取代的嘧啶-硫代烷基和烷基醚化合物

Publications (1)

Publication Number Publication Date
CN1535958A true CN1535958A (zh) 2004-10-13

Family

ID=23733510

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA200410032589XA Pending CN1535958A (zh) 1995-05-08 1996-05-03 α-取代的嘧啶-硫代烷基和烷基醚化合物
CNB961937912A Expired - Fee Related CN1152022C (zh) 1995-05-08 1996-05-03 α-取代的嘧啶-硫代烷基和烷基醚化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB961937912A Expired - Fee Related CN1152022C (zh) 1995-05-08 1996-05-03 α-取代的嘧啶-硫代烷基和烷基醚化合物

Country Status (26)

Country Link
US (1) US6043248A (enExample)
EP (2) EP1449835A3 (enExample)
JP (1) JPH11507017A (enExample)
KR (1) KR100445498B1 (enExample)
CN (2) CN1535958A (enExample)
AT (1) ATE275550T1 (enExample)
AU (1) AU712404B2 (enExample)
BR (1) BR9608265A (enExample)
CA (1) CA2216099C (enExample)
CZ (1) CZ293135B6 (enExample)
DE (1) DE69633332T2 (enExample)
ES (1) ES2227586T3 (enExample)
GE (1) GEP20002297B (enExample)
HU (1) HUP9801995A3 (enExample)
IL (1) IL118075A0 (enExample)
MX (1) MX9708582A (enExample)
NO (1) NO310287B1 (enExample)
NZ (1) NZ307089A (enExample)
PL (1) PL323240A1 (enExample)
PT (1) PT824524E (enExample)
RU (1) RU2167155C2 (enExample)
SK (1) SK150297A3 (enExample)
TW (1) TW450962B (enExample)
UA (1) UA56992C2 (enExample)
WO (1) WO1996035678A1 (enExample)
ZA (1) ZA963281B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101638391B (zh) * 2009-08-21 2011-04-27 山东大学 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3h-嘧啶-4-酮类衍生物及其制备方法与应用

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301800A1 (en) * 1997-09-25 1999-04-22 Pharmacia & Upjohn Company Thioalkyl alpha substituted pyrimidine compounds
US6111111A (en) 1997-10-23 2000-08-29 Kuraray Co., Ltd. Intermediates for producing pyridine derivatives
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
KR20010079842A (ko) 1998-09-17 2001-08-22 스티븐 비. 데이비스 ａＰ2 억제제 또는 조합을 사용한 아테롬성동맥경화증의치료 방법
ATE253915T1 (de) 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
JP2003503351A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害化合物
US6316444B1 (en) 1999-06-30 2001-11-13 Merck & Co., Inc. SRC kinase inhibitor compounds
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
US8852632B2 (en) * 2004-12-03 2014-10-07 Merck Sharp & Dohme Corp. Pharmaceutical formulation containing a release rate controlling composition
HRP20100504T1 (hr) * 2005-03-04 2010-10-31 Tibotec Pharmaceuticals 2-(4-cijanofenil)-6-hidroksilaminopirimidini koji inhibiraju hiv
US7923056B2 (en) 2007-06-01 2011-04-12 Illinois Tool Works Inc. Method and apparatus for dispensing material on a substrate
EP2432776B1 (en) 2009-05-21 2019-09-11 Universite Laval Methyl sulfanyl pyrimidines useful as antiinflammatories, analgesics, and antiepileptics
US9226970B2 (en) 2010-02-22 2016-01-05 Nektar Therapeutics Oligomer modified diaromatic substituted compounds
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
PH12013500011A1 (en) * 2010-07-02 2013-02-18 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat aids
RS57397B8 (sr) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glikoproteini i rekombinantni vektori
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
KR101360587B1 (ko) * 2012-11-01 2014-03-10 현대자동차주식회사 스마트 도어 언록 시스템
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
NZ739226A (en) 2015-07-22 2022-11-25 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
GB201807898D0 (en) * 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
EP4037688A4 (en) * 2019-10-04 2023-09-06 Enanta Pharmaceuticals, Inc. ANTIVIRAL HETEROCYCLIC COMPOUNDS
CA3167672A1 (en) * 2020-01-20 2021-07-29 Agrematch Ltd. Compositions for crop protection
CN114057707A (zh) * 2021-11-24 2022-02-18 上海应用技术大学 一种n-4-吲哚基-2-呋喃甲酰胺化合物的制备方法
EP4463441A1 (en) * 2022-01-12 2024-11-20 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2295560A (en) * 1941-06-18 1942-09-15 Gen Electric Pyrimidine derivatives
GB744867A (en) * 1952-10-29 1956-02-15 American Cyanamid Co Improvements relating to 2-substituted-mercapto-4-amino-6-disubstituted-aminopyrimidines and acid addition salts thereof
US3940394A (en) * 1972-03-31 1976-02-24 Santilli Arthur A 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides
US3940240A (en) * 1974-07-11 1976-02-24 Ina Seito Co., Ltd. Baking method and kiln for tile
EP0124630B1 (de) * 1983-05-05 1987-01-28 LUDWIG HEUMANN & CO GMBH Pyrimidin-Thioalkylpyridin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindung enthaltende Arzneimittel
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
JPS62209062A (ja) * 1986-03-10 1987-09-14 Yamanouchi Pharmaceut Co Ltd ２−ピリジルメチルチオ−または２−ピリジルメチルスルフイニル−置換縮合環化合物
JPH07107056B2 (ja) * 1987-01-30 1995-11-15 日清製粉株式会社 ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤
AU3752589A (en) * 1988-05-16 1989-12-12 Georgia State University Research Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
HU203736B (en) * 1989-04-06 1991-09-30 Gyogyszerkutato Intezet Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them
CA2071529C (en) * 1989-12-28 2001-03-20 Donna Lee Romero Diaromatic substituted anti-aids compounds
US5668136A (en) * 1990-09-25 1997-09-16 Eisai Co., Ltd. Trisubstituted benzene derivatives, composition and methods of treatment
AU653855B2 (en) * 1991-07-03 1994-10-13 Pharmacia & Upjohn Company Indolyl carbonyl pyridinyl-poperazine/piperidine derivatives
GB2266716A (en) * 1992-05-05 1993-11-10 Merck & Co Inc Inhibitors of HIV reverse transcriptase
JP3077046B2 (ja) * 1992-08-31 2000-08-14 久光製薬株式会社 新規なキナゾリン誘導体
JPH09502713A (ja) * 1993-09-17 1997-03-18 ジ・アップジョン・カンパニー Ｈｉｖおよび他のレトロウイルス病を治療するのに有用な置換テトロン酸
NZ276286A (en) * 1993-11-12 2001-06-29 Upjohn Co Substituted pyrimidine thio- or oxy-alkyl derivatives and medicaments
AU2395095A (en) * 1994-04-29 1995-11-29 G.D. Searle & Co. Method of using (h+/k+) atpase inhibitors as antiviral agents
EP0772593B1 (de) * 1994-07-20 2003-05-02 ALTANA Pharma AG Pyridylthioverbindungen zur bekämpfung von helicobacter-bakterien

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101638391B (zh) * 2009-08-21 2011-04-27 山东大学 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3h-嘧啶-4-酮类衍生物及其制备方法与应用

Also Published As

Publication number Publication date
NO975129D0 (no) 1997-11-07
UA56992C2 (uk) 2003-06-16
KR19990008400A (ko) 1999-01-25
PT824524E (pt) 2005-01-31
HUP9801995A3 (en) 1999-04-28
CA2216099A1 (en) 1996-11-14
KR100445498B1 (ko) 2004-11-16
EP0824524B1 (en) 2004-09-08
BR9608265A (pt) 1999-02-02
CZ293135B6 (cs) 2004-02-18
JPH11507017A (ja) 1999-06-22
HK1009446A1 (en) 1999-09-10
DE69633332T2 (de) 2005-09-22
NO975129L (no) 1998-01-07
HUP9801995A2 (hu) 1999-03-29
EP0824524A1 (en) 1998-02-25
DE69633332D1 (de) 2004-10-14
AU5635396A (en) 1996-11-29
AU712404B2 (en) 1999-11-04
US6043248A (en) 2000-03-28
WO1996035678A1 (en) 1996-11-14
MX9708582A (es) 1998-02-28
EP1449835A3 (en) 2004-09-15
CN1183773A (zh) 1998-06-03
ZA963281B (en) 1997-10-24
IL118075A0 (en) 1996-08-04
RU2167155C2 (ru) 2001-05-20
CZ349197A3 (cs) 1998-04-15
NZ307089A (en) 1999-07-29
NO310287B1 (no) 2001-06-18
GEP20002297B (en) 2000-11-25
ES2227586T3 (es) 2005-04-01
EP1449835A2 (en) 2004-08-25
SK150297A3 (en) 1998-10-07
TW450962B (en) 2001-08-21
CN1152022C (zh) 2004-06-02
PL323240A1 (en) 1998-03-16
ATE275550T1 (de) 2004-09-15
CA2216099C (en) 2005-09-13

Similar Documents

Publication Publication Date Title
CN1535958A (zh) α-取代的嘧啶-硫代烷基和烷基醚化合物
CN1051544C (zh) 苯磺酰胺衍生物及其制备方法
CN1136216C (zh) 吡啶酮羧酸衍生物或其盐以及以它们为有效成分的抗菌剂
CN1300116C (zh) 1h－吲唑化合物
CN1234693C (zh) 抑制蛋白激酶的吲唑化合物和药物组合物及它们的应用
CN1656073A (zh) 可用于治疗蛋白激酶依赖性疾病的二芳基脲衍生物
CN1071917A (zh) 用作人类免疫缺陷病毒逆转录酶拮抗剂的喹唑啉衍生物
CN1090274A (zh) 缩合杂环化合物和其制备方法及应用
CN101035769A (zh) 作为激酶抑制剂的嘧啶脲衍生物
CN1290249A (zh) 氨基胍腙衍生物、制法及制剂
CN1419545A (zh) 作为蛋白激酶抑制剂的3－氰基喹啉、3－氰基－1,6－二氮杂萘和3－氰基－1,7－二氮杂萘
CN1623984A (zh) 稠环化合物及其药物用途
CN1246856A (zh) 芳基和杂芳基取代的稠合吡咯抗炎药
CN1675225A (zh) 大环嘧啶化合物、其制备方法以及作为药物的应用
CN1073174A (zh) 杂环衍生物
CN1438890A (zh) 腺苷受体调制剂
CN1694873A (zh) 辣椒素受体配体及其治疗用途
CN1788001A (zh) 可用于治疗赘生性疾病、炎性和免疫系统病症的2,4－二(苯氨基)嘧啶
CN1511830A (zh) 作为消炎剂的化合物
CN1524079A (zh) 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
CN1157617A (zh) 杂双环衍生物
CN1495170A (zh) 用于治疗炎症的取代的吡唑基苯磺酰胺类化合物
CN1179156A (zh) 作为5－ht受体拮抗剂的吲哚衍生物
CN1867553A (zh) 作为cdk 和/或vegf 抑制剂的氨基亚砜取代的嘧啶化合物、其制备方法以及作为药物的用途
CN1933839A (zh) 化合物和使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1066540

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1066540

Country of ref document: HK